Clinical Trials Logo

HHT clinical trials

View clinical trials related to HHT.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06039124 Completed - HHT Clinical Trials

Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

BEST
Start date: September 1, 2021
Phase:
Study type: Observational

Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment. We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.

NCT ID: NCT02389959 Completed - Epistaxis Clinical Trials

Intranasal Bevacizumab for HHT-Related Epistaxis

Start date: August 4, 2014
Phase: Phase 4
Study type: Interventional

This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.

NCT ID: NCT01314274 Completed - Epistaxis Clinical Trials

Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Start date: March 2011
Phase: Phase 2
Study type: Interventional

In a case series intranasal submucosal bevacizumab has been shown to reduce epistaxis in patients suffering from Hereditary Haemorrhagic Telangiectasia together with KTP Laser therapy. The aim of this study is to evaluate the effectiveness of submucosal intranasal bevacizumab compared to placebo in a randomized double blind trial setting.